Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2013

MTPC Agreement for 2012 or 2011:



	2012		2011
	(in thousands)
Amortized portion of up-front payments	$	12,744	$	38,232
Milestone revenues	485		68,515
Payments for manufacturing services	5,650		14,928
Total collaborative revenues attributable to the Mitsubishi Tanabe collaboration	$	18,879	$	121,675

During the three years ended December 31, 2013, the Company recognized the following revenues attributable to the Janssen collaboration:



	2013		2012			2011
	(in thousands)
Royalty revenues	$	130,724	$	117,592		$	20,289
Collaborative revenues:
Up-front and amendment payments revenues	$	190,345	$	12,428		$	12,428
Milestone revenues	—		—			250,000
Net reimbursement (payment) for telaprevir development costs	2,793		(3,507		)	(8,418		)
Reimbursement for manufacturing services	10,299		7,257			20,383
Total collaborative revenues attributable to the Janssen collaboration	$	203,437	$	16,178		$	274,393
Total revenues attributable to the Janssen collaboration	$	334,161	$	133,770		$	294,682

Summary of activity related to net loss (income) attributable to noncontrolling interest (Alios)

A summary of net loss (income) attributable to noncontrolling interest (Alios) for the three years ended December 31, 2013 is as follows:



	2013			2012			2011
	(in thousands)
Loss before provision for (benefit from) income taxes	$	283,747		$	20,044		$	9,536
Decrease (increase) in fair value of contingent milestone and royalty payments	124,920			(114,970		)	(69,950		)
Provision for (benefit from) income taxes	(166,145		)	39,029			48,809
Net loss (income) attributable to noncontrolling interest (Alios)	$	242,522		$	(55,897	)	$	(11,605	)

Summary of Alios' items included in the Company's consolidated balance sheets

Alios Balance Sheet Information

The Company included items related to Alios on the Company's consolidated balance sheet as of December 31, 2012. Due to the deconsolidation of Alios as of December 31, 2013, these items were not included on the Company's consolidated balance sheet as of December 31, 2013. The following table summaries items related to the Alios included on the Company's consolidated balance sheet as of December 31, 2012.



	As of December 31, 2012
		(in thousands)
Restricted cash and cash equivalents (Alios)		$	69,983
Prepaid expenses and other current assets		$	672
Property and equipment, net		$	1,728
Intangible assets		$	250,600
Other assets		$	861
Accounts payable		$	1,054
Accrued expenses		$	6,099
Income taxes payable (Alios)		$	715
Deferred tax liability		$	152,781
Other liabilities, excluding current portion		$	910
Redeemable noncontrolling interest (Alios)		$	38,530
Noncontrolling interest (Alios)		$	196,672

As of December 31, 2012, the Company recorded Alios’ cash and cash equivalents as restricted cash and cash equivalents (Alios) because (i) the Company did not have any interest in or control over Alios’ cash and cash equivalents and (ii) the Alios Agreement did not provide for these assets to be used for the development of the assets that the Company licenses from Alios pursuant to the Alios Agreement. Assets recorded as a result of consolidating Alios’ financial condition into the Company’s consolidated balance sheet did not represent additional assets that could have been used to satisfy claims against the Company’s general assets.